2 completed. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow Adrian Vella: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effects of Glucagon on Hepatic Metabolism Glucagon response study - Obesity, Type2diabetes | Phase 1 / Phase 2 | Completed | Adrian Vella | 21 | 2022-10-20 | 2026-10-14 |
| Dose-response Study of Exendin-9,39 on Glucose Metabolism saline infusion, GLP-1-9,36 infusion, Exendin-9,39 at low dose - Pancreatic Effects of 9,39-Exendin and 9,36-GLP-1 | Phase 1 | Completed | Adrian Vella | 11 | 2011-05-01 | 2013-01-23 |
Fatty Liver (1) · Insulin Resistance (1) · Non-alcoholic Fatty Liver Disease (1) · Obesity (1)
Glucagon (1)
United States (2)
R01DK116231 (1)